Trial Schema and Aims

* The carboplatin dose recommended for ICON7 is AUC6 (unless predetermined as being different by individual GCIG group) **Bevacizumab can be omitted from the first cycle if cytotoxic chemotherapy must be started within 4 weeks of surgery

Primary outcome measure:

Progression Free Survival (PFS)

Secondary outcome measures:

 Overall Survival (OS) Response Rate and Duration of Response Biological Progression Free Interval (PFIBIO) Safety

Related ICON7 Substudies:

Quality of Life (QoL) Health Economics (HE) Translational (biomarker) Research